Bolt Therapeutics Conference Call - BOLT BIOTHERAPEUTICS INC

Explicit Guidance:

• Financing Proceeds: $120 million in upfront gross proceeds from concurrent private placement; potential additional $60 million in gross proceeds upon exercise of accompanying warrants.
• Runway: $120 million in upfront proceeds expected to fund operations into 2026E.
• Clinical Milestones:
  • 2027: Expected proof-of-concept Phase 2 data for lead program PRA216; initial clinical data expected from second program (IL-31 bispecific) in atopic dermatitis.
  • Second Half 2027: Programs 3 and 4 expected to advance through IND-enabling development; potential data readouts for all programs beginning in Q2 2027 through Q4 2027.
  • Q2–Q4 2027: Patient proof-of-concept data across all four PRA216 studies (Asthma, COPD, Atopic Dermatitis, EOE) expected.
• Pivotal Trials: Phase III enabling activities progressing; PRA216 positioned to enter pivotal trials in early 2028.
• Regulatory/Corporate: Non-voting convertible preferred stock expected to convert into BOLT common stock following planned stockholder vote.

Business-Segment Outlook:

• Primary Focus: Prana Therapies pipeline expected to become the primary development focus following the reverse merger.
• Pipeline Progression:
  • Lead Program (PRA216): Currently in Phase II development; targeting multiple high-value inflammatory indications (Asthma, COPD, Atopic Dermatitis, EOE).
  • Second Program: IL-31 containing bispecific, initially for atopic dermatitis, moving into clinic and generating data in H2 2027.
  • Discovery Pipeline: Platform expected to generate new wholly-owned programs (Programs 3 & 4) to advance through IND-enabling in H2 2027.
• Dosing Strategy: Phase II evaluating every 8-week maintenance dosing; future trials may evaluate every 12-week dosing intervals.
• Team Expansion: Dr. Sheila Gujarati appointed Chief Strategy Officer and Board Member; team includes deep expertise in immunology and complex biologics.

Market and Competitive Outlook:

• Target Markets: Focused on large global markets with hundreds of millions of patients (Asthma, COPD, Atopic Dermatitis) where biologics have established standard of care but unmet need remains.
• Value Proposition: Aiming to exceed efficacy ceilings of monotherapies by combining IL-4 receptor alpha and TSLP blockade to treat heterogeneous patient populations and comorbid atopic conditions.
• Differentiation: Platform designed to provide "best in disease" therapy via durable efficacy for chronic diseases with infrequent at-home dosing (subcutaneous auto-injector).
• Competitive Landscape: Believes current monotherapies leave room for improvement in reducing exacerbation rates; aims to deliver deeper and more durable efficacy through dual-target inhibition.

Macro / Industry Outlook:

• Industry Trends: Management highlights a trend of "best in disease" requirements for chronic inflammatory therapies, emphasizing convenience and patient-friendly dosing profiles.
• Platform Validation: Clinical data from Phase I viewed as validation for the "whole product profile" approach (efficacy + convenience) in the biologics sector.
• No specific macroeconomic variables (rates, FX, tariffs) or broader economic forecasts were discussed in the transcript.

Strategic Initiatives:

• M&A: Completed acquisition of Prana Therapies via reverse merger (stock for stock, sign and close) on October 23rd.
• Platform Expansion: INSPIRE platform (half-life-extended multispecific antibodies) expected to expand into additional indications and generate new candidates.
• Operational Acceleration: Rapid advancement from Phase I to Phase II based on favorable safety/PK data; parallel progression of Phase III enabling activities.
• Financial Structure: Capitalization optimized to support clinical milestones and platform validation through 2026 and beyond.

Risks and Headwinds to Outlook:

• Clinical Uncertainty: Future milestones (POC data in 2027, Phase III entry in 2028) are subject to risks and uncertainties; data readouts could differ from expectations.
• Regulatory/Corporate: Conversion of preferred stock is "subject to stockholder approval."
• Scientific Risks: Potential for immunogenicity (though currently low at 2.3%), dosing regimen limitations, or failure to demonstrate superior efficacy over monotherapies in patient populations.
• Standard Forward-Looking Statement Warning: All remarks concerning financing, clinical development, and milestones are subject to risks and uncertainties described in SEC filings.

Management Tone on the Future:

• Confidence Level: High confidence; management describes the outlook as "exciting," "catalyst-rich," and a "compelling path forward."
• Speed: Emphasis on moving "rapidly" into Phase II and executing an efficient development strategy.
• Validation: Tone suggests strong validation of the INSPIRE platform through Phase I data, with expectations to translate this into "meaningful clinical benefit" in Phase II.
• Future Outlook: Describes 2027 and beyond as potentially "catalyst-rich" with multiple important milestones expected over the next 12–18 months.

Miscellaneous:

• Target Biology: PRA216 targets IL-4 receptor alpha (IL-4Rα) and TSLP to inhibit both downstream and upstream type 2 inflammation.
• Platform Technology: INSPIRE platform utilizes a fully human IgG-based architecture with YTE modified Fc for improved stability, manufacturability, high concentration subcutaneous formulation, and decreased immunogenicity.
• Safety Profile: Phase I data (57 healthy volunteers) showed no serious adverse events, no injection site reactions, and very low immunogenicity.